Jeppe Brinck-Jensen works with intellectual property law. He renders advice on primarily disputes and agreements in the areas of patents, trademarks and trade secrets to research enterprises in the life sciences, medical, cleantech and food industries in particular.
He is one of Denmark's most experienced litigators in intellectual property proceedings.
Chambers places Jeppe Brinck-Jensen in Band 1 in intellectual property law.
Recent major legal proceedings:
- Illumina vs. BGI – patent for gen sequencing device
- Teva vs. Mylan (copemyl) – Patent for Copaxone®
- Chr. Hansen vs. DuPont (bifidobacterium) - Trademark right in BB12®
- Demant vs. Retune – Patent for noise-reducing algorithm - trade secrets
- Valmet Automation vs. Emco – trade secrets
- Astra Zeneca vs. Krka (esomeprazol) – Patent for Nexium®
- Gilead vs. Accord et al. - (tenofivir dispoproxil + emtricitabine) – SPC for Truvada® and Atripla®
- Novartis vs. Orifarm Generics - (rivastigmine) – Patent for Exelon®
- Mirrx Therapeutics vs. Santaris Pharma A/S – Right in invention regarding RNA
- Merck vs. Orifarm - (montelukast) - parallel import – Trademark for Nuvaring®
- Merck vs. Orifarm - specific mechanism – SPC for Singulair®
(A number of the above cases were conducted by Jeppe before he joined Bech-Bruun)